Medication-refractory nausea and vomiting, which is often due to gastric dysmotility, is a challenging problem. High-frequency gastric electrical stimulation (GES), which was approved by the U.S. Food and Drug Administration in 2000, can offer a viable palliative option for these patients. This multicenter study prospectively collected data from patients who underwent GES implantation for refractory nausea and\/or vomiting to assess the efficacy, safety, and medico-economic impact of this treatment. <\/p>\n\n\n\n
The investigators collected clinical data from 142 patients (60 with diabetes, 82 without diabetes) and medico-economic data for 96 patients (36 with diabetes, 60 without diabetes) 2 years after GES placement. The Gastrointestinal Quality of Life Index score, a questionnaire that addresses nausea and dyspeptic symptoms as well as quality of life, increased by 12.1 \u00b1 25.0 points (P<\/em><.001), with a more significant improvement in patients without diabetes than those with diabetes (15.8 \u00b1 25.0 points [P<\/em><.001] vs 7.3 \u00b1 24.5 points [P<\/em>=.027], respectively). Overall vomiting significantly improved, with a 25.5% (P<\/em><.001) increase in the proportion of patients vomiting less than once per month. Costs incurred included hospitalizations, time off work, and transport. GES decreased mean overall health care costs from $8873 to $5525 per patient per year (P<\/em>=.001), representing an annual savings of $3348 per patient. Savings were greater for patients with diabetes ($4096 per patient annually) than for patients without diabetes ($2900 per patient annually). Although 25.4% of the patients had at least 1 device-related adverse event, no patients had major complications that required device removal.<\/p>\n","protected":false},"excerpt":{"rendered":" Medication-refractory nausea and vomiting, which is often due to gastric dysmotility, is a challenging problem. High-frequency gastric electrical stimulation (GES), which was approved by the U.S. Food and Drug Administration in 2000, can offer a viable palliative option for these patients. This multicenter study prospectively collected data from patients who underwent GES implantation for refractory … Read more<\/a><\/p>\n","protected":false},"template":"","categories":[1768,1789],"tags":[2519,2518,2103,2520],"class_list":["post-9637","ec-news","type-ec-news","status-publish","hentry","category-asge-journal-scan","category-stomach-and-small-bowel","tag-gastric-electrical-stimulation","tag-ges","tag-stomach-2","tag-vomiting-2"],"_links":{"self":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news\/9637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news"}],"about":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/types\/ec-news"}],"wp:attachment":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/media?parent=9637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/categories?post=9637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/tags?post=9637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}